Vistagen receives u.s. patent for av-101 to treat neuropathic pain

South san francisco, calif.--(business wire)--vistagen (nasdaq: vtgn), a clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that the u.s. patent and trademark office (uspto) granted a patent to the company for its oral non-opioid product candidate, av-101, for the treatment of neuropathic pain. the patent will not expire until at least 2034 and is part of vistage.
VTGN Ratings Summary
VTGN Quant Ranking